HRP20181782T2 - Peptidno cjepivo pcsk9 - Google Patents
Peptidno cjepivo pcsk9 Download PDFInfo
- Publication number
- HRP20181782T2 HRP20181782T2 HRP20181782TT HRP20181782T HRP20181782T2 HR P20181782 T2 HRP20181782 T2 HR P20181782T2 HR P20181782T T HRP20181782T T HR P20181782TT HR P20181782 T HRP20181782 T HR P20181782T HR P20181782 T2 HRP20181782 T2 HR P20181782T2
- Authority
- HR
- Croatia
- Prior art keywords
- vaccine
- seq
- group
- peptide
- use according
- Prior art date
Links
- 101150094724 PCSK9 gene Proteins 0.000 title 1
- 229940023041 peptide vaccine Drugs 0.000 title 1
- 229960005486 vaccine Drugs 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 3
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 229960000814 tetanus toxoid Drugs 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 101710188053 Protein D Proteins 0.000 claims 1
- 101710132893 Resolvase Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (10)
1. Cjepivo, naznačeno time, da sadrži najmanje jedan peptid odabran iz skupine koju čine SIPWSLERIT (SEQ ID NO: 21), VIPWNLERIL (SEQ ID NO: 55), i SVPWNLERIQ (SEQ ID NO: 60), pri čemu je taj najmanje jedan peptid vezan ili fuzioniran s farmaceutski prihvatljivim nosačem.
2. Cjepivo prema patentnom zahtjevu 1, naznačeno time, da najmanje jedan peptid na svojem N-završetku i/ili C-završetku sadrži najmanje jedan cisteinski ostatak koji je izravno vezan na njih ili je vezan preko međurazdjelnog slijeda.
3. Cjepivo prema patentnom zahtjevu 1 ili 2, naznačeno time, da se kod farmaceutski prihvatljivog nosača radi o proteinskom nosaču.
4. Cjepivo prema patentnom zahtjevu 3, naznačeno time, da je proteinski nosač odabran iz skupine koju čine Keyhole Limpet hemocijanin (KLH), tetanus toksoid (TT), protein D, ili difterijski toksin (DT), poželjno mutirani difterijski toksin, a još poželjnije CRM197.
5. Cjepivo prema bilo kojem od patentnih zahtjeva 1 do 4, naznačeno time, da se cjepivo formulira s pomoćnim sredstvom, a poželjno se adsorbira na Alhidrogel.
6. Cjepivo prema bilo kojem od patentnih zahtjeva 1 do 5, naznačeno time, da je za uporabu u postupku za liječenje i/ili prevenciju poremećaja koji su prouzročeni hiperlipidemijom, hiperkolesterolemijom i/ili aterosklerozom, posebno za kardiovaskularne bolesti, moždani udar ili periferne vaskularne bolesti.
7. Cjepivo, naznačeno time, da se sastoji od aminokiselinskog slijeda odabranog iz skupine koju čine SIPWSLERIT (SEQ ID NO: 21), VIPWNLERIL (SEQ ID NO: 55), i SVPWNLERIQ (SEQ ID NO: 60).
8. Cjepivo za uporabu prema patentnom zahtjevu 6, naznačeno time, da se peptidi primjenjuju na sisavcu ili na pojedincu u količini od 0,1 ng do 10 mg, poželjno od 0,5 do 500 μg, još poželjnije od 1 do 100 μg, po imunizaciji.
9. Cjepivo za uporabu prema patentnom zahtjevu 6 ili 8, naznačeno time, da se cjepivo primjenjuje između 2 i 10 puta, poželjno između 2 i 7 puta, još poželjnije do 5 puta, a najpoželjnije najviše do 4 puta.
10. Cjepivo za uporabu prema bilo kojem od patentnih zahtjeva 6, 8 ili 9, naznačeno time, da cjepivo sadrži peptide u količini od 0,5 do 500 μg, poželjno od 1 do 100 μg, ili alternativno od 100 fmola do 10 μmola, poželjno od 10 pmola do 1 μmol, posebno od 100 pmola do 100 nmola.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12182241.5A EP2703483A1 (en) | 2012-08-29 | 2012-08-29 | PCSK9 peptide vaccine |
PCT/EP2013/067797 WO2014033158A2 (en) | 2012-08-29 | 2013-08-28 | Vaccine |
EP13756108.0A EP2890785B1 (en) | 2012-08-29 | 2013-08-28 | Pcsk9 peptide vaccine |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20181782T1 HRP20181782T1 (hr) | 2019-02-08 |
HRP20181782T2 true HRP20181782T2 (hr) | 2024-06-21 |
Family
ID=46785271
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20181782TT HRP20181782T2 (hr) | 2012-08-29 | 2013-08-28 | Peptidno cjepivo pcsk9 |
Country Status (21)
Country | Link |
---|---|
US (5) | US9533030B2 (hr) |
EP (3) | EP2703483A1 (hr) |
JP (2) | JP6298820B2 (hr) |
KR (1) | KR102101201B1 (hr) |
CN (2) | CN107837392A (hr) |
AR (2) | AR092377A1 (hr) |
AU (2) | AU2013307319B2 (hr) |
CA (1) | CA2881318C (hr) |
CY (1) | CY1121067T1 (hr) |
DK (1) | DK2890785T3 (hr) |
ES (1) | ES2693572T3 (hr) |
HK (1) | HK1249859A1 (hr) |
HR (1) | HRP20181782T2 (hr) |
HU (1) | HUE040469T2 (hr) |
LT (1) | LT2890785T (hr) |
PL (1) | PL2890785T3 (hr) |
PT (1) | PT2890785T (hr) |
SI (1) | SI2890785T1 (hr) |
TR (1) | TR201815497T4 (hr) |
TW (1) | TWI615148B (hr) |
WO (1) | WO2014033158A2 (hr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2703483A1 (en) * | 2012-08-29 | 2014-03-05 | Affiris AG | PCSK9 peptide vaccine |
BR112018008697A2 (pt) * | 2015-11-03 | 2018-10-30 | Affiris Ag | método e kit para vacinação contra um auto-antígeno, uso de um kit, e, vacina para uso em vacinação. |
CN106822881A (zh) * | 2016-12-09 | 2017-06-13 | 四川大学 | 一种针对pcsk9的抗高血脂蛋白疫苗 |
KR102401796B1 (ko) * | 2017-04-13 | 2022-05-25 | 카딜라 핼쓰캐어 리미티드 | 신규의 펩타이드 기재 pcsk9 백신 |
CN114672476A (zh) * | 2022-01-14 | 2022-06-28 | 复旦大学附属中山医院 | 人pcsk9蛋白的优势构象表位及其应用 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
JP3755890B2 (ja) | 1992-06-25 | 2006-03-15 | スミスクライン・ビーチャム・バイオロジカルス(ソシエテ・アノニム) | アジュバント含有ワクチン組成物 |
EP0812593B8 (en) | 1993-03-23 | 2010-11-10 | SmithKline Beecham Biologicals S.A. | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
EP1167379A3 (en) | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
JP3959746B2 (ja) | 1995-06-07 | 2007-08-15 | ペプスキャン システムズ ベー.フェー. | 改良ペプチド、免疫原性組成物およびワクチンまたは医薬製剤、lhrhホルモンに対する動物の免疫方法、ならびにlhrh縦列反復ペプチドおよびそのワクチンとしての使用 |
US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
EP1537877A3 (en) | 1996-10-11 | 2005-08-03 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
EP0971739B1 (en) | 1997-04-01 | 2004-10-06 | Corixa Corporation | Aqueous immunologic adjuvant compositions of monophosphoryl lipid a |
GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
AUPR593101A0 (en) | 2001-06-26 | 2001-07-19 | Council Of The Queensland Institute Of Medical Research, The | Cytomegalovirus t cell epitopes |
US7378384B2 (en) | 2002-09-20 | 2008-05-27 | International Institute Of Cancer Immunology, Inc. | WT1 substitution peptides |
GB0411411D0 (en) | 2004-05-21 | 2004-06-23 | Glaxosmithkline Biolog Sa | Vaccines |
US20100233177A1 (en) * | 2007-04-13 | 2010-09-16 | David Langdon Yowe | Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9) |
AU2009221419B2 (en) * | 2008-02-01 | 2013-09-26 | Alpha-O Peptides Ag | Self-assembling peptide nanoparticles useful as vaccines |
NZ620441A (en) * | 2009-09-03 | 2015-08-28 | Pfizer Vaccines Llc | Pcsk9 vaccine |
EP2450382A1 (de) * | 2010-11-04 | 2012-05-09 | Affiris AG | Immunogenes Peptid |
RS54639B1 (en) * | 2011-09-13 | 2016-08-31 | Affiris Ag | PCSK9 VACCINE |
EP2703483A1 (en) * | 2012-08-29 | 2014-03-05 | Affiris AG | PCSK9 peptide vaccine |
-
2012
- 2012-08-29 EP EP12182241.5A patent/EP2703483A1/en not_active Withdrawn
-
2013
- 2013-08-26 TW TW102130502A patent/TWI615148B/zh active
- 2013-08-28 LT LTEP13756108.0T patent/LT2890785T/lt unknown
- 2013-08-28 CA CA2881318A patent/CA2881318C/en active Active
- 2013-08-28 EP EP13756108.0A patent/EP2890785B1/en active Active
- 2013-08-28 HU HUE13756108A patent/HUE040469T2/hu unknown
- 2013-08-28 WO PCT/EP2013/067797 patent/WO2014033158A2/en active Application Filing
- 2013-08-28 EP EP18179778.8A patent/EP3409770A3/en active Pending
- 2013-08-28 ES ES13756108.0T patent/ES2693572T3/es active Active
- 2013-08-28 JP JP2015529001A patent/JP6298820B2/ja active Active
- 2013-08-28 CN CN201711057619.6A patent/CN107837392A/zh active Pending
- 2013-08-28 AU AU2013307319A patent/AU2013307319B2/en active Active
- 2013-08-28 DK DK13756108.0T patent/DK2890785T3/en active
- 2013-08-28 PL PL13756108T patent/PL2890785T3/pl unknown
- 2013-08-28 PT PT13756108T patent/PT2890785T/pt unknown
- 2013-08-28 HR HRP20181782TT patent/HRP20181782T2/hr unknown
- 2013-08-28 SI SI201331240T patent/SI2890785T1/sl unknown
- 2013-08-28 US US14/418,139 patent/US9533030B2/en active Active
- 2013-08-28 CN CN201380040051.0A patent/CN104685053B/zh active Active
- 2013-08-28 TR TR2018/15497T patent/TR201815497T4/tr unknown
- 2013-08-28 KR KR1020157008006A patent/KR102101201B1/ko active IP Right Grant
- 2013-08-29 AR ARP130103067A patent/AR092377A1/es not_active Application Discontinuation
-
2016
- 2016-12-02 US US15/367,711 patent/US9999659B2/en active Active
-
2017
- 2017-10-25 JP JP2017206158A patent/JP2018048177A/ja active Pending
-
2018
- 2018-05-21 US US15/984,800 patent/US10933123B2/en active Active
- 2018-07-19 HK HK18109348.0A patent/HK1249859A1/zh unknown
- 2018-11-05 CY CY181101153T patent/CY1121067T1/el unknown
- 2018-12-13 AU AU2018278933A patent/AU2018278933A1/en not_active Abandoned
-
2021
- 2021-01-11 US US17/145,571 patent/US11980657B2/en active Active
-
2023
- 2023-01-31 AR ARP230100224A patent/AR128395A2/es unknown
-
2024
- 2024-02-28 US US18/589,494 patent/US20240197844A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181782T2 (hr) | Peptidno cjepivo pcsk9 | |
AR107020A2 (es) | Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9) | |
AR125327A2 (es) | Composiciones de neisseria meningitidis y métodos de las mismas | |
EA200802170A1 (ru) | Лиофилизированная композиция терапевтического пептидного антитела | |
EA033386B1 (ru) | Рекомбинантные иммуногенные полипептиды стеблевого домена гемагглютинина вируса гриппа а и их применение | |
NO20083793L (no) | Antistoffer mot amyloid-beta peptid | |
MX2018011836A (es) | Conjugados de anticuerpo farmaco anti-cd70. | |
MX351414B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico. | |
ES2585328T3 (es) | Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis | |
PE20121393A1 (es) | Analogo peptidico de oxintomodulina | |
MX2012008999A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
MX340015B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
MX2012009000A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
WO2008124646A3 (en) | Use of amyloid proteins as vaccine scaffolds | |
NZ612315A (en) | Compositions for immunising against staphylococcus aureus | |
RU2015122368A (ru) | Слитые белки для применения в качестве иммуногенных усиливающих агентов для индуцирования антигенспецифического т-клеточного ответа | |
IN2014KN01716A (hr) | ||
IN2014KN01714A (hr) | ||
RU2014114506A (ru) | Вакцина | |
HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
HK1126856A1 (en) | Methods for identifying polypeptide targets | |
UA107180C2 (uk) | Туберкульозний білок rv1753c, композиція, що його містить, та застосування | |
RU2016138365A (ru) | Pcsk9 вакцины | |
WO2013021284A3 (en) | Anti-il-6 vaccine composition | |
JP2015528453A5 (hr) |